Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra long-acting β2-adrenoceptor agonist (uLABA), with formoterol in patients with asthma.
Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β2-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This single-dose crossover study was conducted to investigate and compare with formoterol the br
